Ario Pharma Strengthens Scientific Advisory Board with Two Key Appointments
Ario Pharma Ltd, the Cambridge biopharmaceutical company developing innovative new approaches to treat respiratory disease, has appointed Professor Peter Barnes DM, DSc, FRCP, FCCP, FMedSci, FRS and Professor Wisia Wedzicha MA, MD, FRCP, FMedSci to its Scientific Advisory Board (SAB) with immediate effect.
Peter Barnes is Margaret Turner-Warwick Professor of Medicine at the National Heart and Lung Institute, Head of Respiratory Medicine at Imperial College and Honorary Consultant Physician at Royal Brompton Hospital, London. He qualified at Cambridge and Oxford Universities and was appointed to his present post in 1987. He has published more than 1000 peer-review papers on asthma, COPD (chronic obstructive pulmonary disease) and related topics and has written or edited in excess of 50 books. He is the 7th most highly cited researcher in the world, has been the most highly cited clinical scientist in Europe and the most highly cited respiratory researcher in the world over the last 20 years. Elected a Fellow of the Royal Society in 2007, Professor Barnes is currently President of the European Respiratory Society. He co-founded an Imperial spin-out company RespiVert, which was acquired by Johnson & Johnson and has developed novel inhaled treatments for COPD and severe asthma.
Wisia Wedzicha is Professor of Respiratory Medicine at the National Heart and Lung Institute, Imperial College London, UK. She qualified from Somerville College, Oxford University and St Bartholomew’s Hospital Medical College, University of London. Professor Wedzicha has a particular interest in the causes, mechanisms, impact and prevention of COPD exacerbations and in the role of bacterial and viral infection at COPD exacerbation. She directs an active research group into COPD exacerbations and has published extensively on this topic. Professor Wedzicha was a member of the Guideline Development Group for the revision of the National Institute for Healthcare and Clinical Excellence COPD Guidelines.
Dr John Ford, CEO of Ario Pharma, commented: “We are very pleased to welcome two eminent respiratory physicians from the world-leading Imperial College respiratory medicine group to the SAB, joining international medical experts such as Professor Maria Belvisi, Head of the Respiratory Pharmacology group at the National Heart and Lung Institute at Imperial College. The SAB will serve as a strategic resource to assist Ario Pharma in the planning, design and implementation of clinical trials. Peter and Wisia will also play a key role in advising the Company on the development of new targets for respiratory disease.”
Ario Pharma recently commenced a Phase IIa study of its TRPV1 antagonist, XEN-0501, for the treatment and prevention of cough in patients with chronic obstructive pulmonary disease (COPD).
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance